Alumni of 500 Startups.
220,000+ hosts over 135 countries.
Raised $13.5M USD to date from institutional investors like Project A and Ventech.
PROVEN SALES: $8M+ lifetime revenue; expected $3M revenue for 2018
PROVEN GROWTH: 42-152% year-over-year growth
PROVEN PROFITABILITY: Net income positive 5 consecutive years since launch in 2013.
On track for $3.5M in sales this year, up from $1.17M in 2017.
Grown 100+ percent each year since launch.
Raised $968K in pre-seed round.
This is a limited opportunity to own an equity stake in Chattanooga Football Club. Supporter shares are limited to 8,000. This is real equity with real rights—each share comes with life-long voting rights and special owner privileges.
We have inspired dozens of community-based clubs throughout the United States, giving them hope that soccer can thrive in places we never thought possible. A successful raise will set an example and pave the way for other clubs and cities across America.
By becoming an owner, you’re not just investing in the local soccer community, as shareholder of a benefit corporation, you’re buying a piece of U.S. soccer history.
10x more effective than conventional antivenom.
Our antivenom saved 100% of mice from whole snake venom.
Our antivenom is made in bacteria instead of horses = cheaper and faster to produce.
CEO's prior two companies were acquired by Qualcomm and Apple, with technologies now standards in the industry.
Over $30M of non-dilutive funding (peer-reviewed grants rewarding innovation above 'hot' target trends) has driven the research and development.
Extensive evidence, including a proof-of-concept study in humans, showing a reversal of PN through 1) nerve regrowth, 2) reduced symptoms, and 3) return of quality-of-life to patients.
First brew sold out in 4 days. Second sold out in two days. The brand was immediately profitable.
Available in 150+ stores. Adding 5-10 new stores each week.
40% of consumers repurchase.
Profitable – 11% monthly growth rate since Q2 2016.
290% yearly growth in paying subscribers.
500,000+ registered athletes in 150+ countries.
Raised $1M in two previous rounds.
Key innovation: partially submerging infant in synthetic amniotic fluid that replicates the temperature and environment of the womb.
Built prototype in April 2018. Currently in pre-clinical tests.
Privacy: We won’t share your data, or post to your wall, without your permission.
Already have an account? Login
Don't have an account? Signup